Almac Continues Transition to New North American Headquarters
Already cleared as a TSA Certified Cargo Screening Facility, the next step for the company is to relocate their label generation, controlled substance packaging, and primary packaging operations. Almac anticipates the phased transfer, which began in November, to be complete by February 2011 sequentially making both buildings in the headquarters project fully operational. A copy of the proposed dates of transfer can be viewed by visiting the NAHQ specific microsite.
The new headquarters houses clinical trial supply and technology services as well as introducing Almac’s analytical services to the USfor the first time. This combination of services optimizes the clinical supply chain by providing clients with the ability to approve multiple activities at one site, in one visit. In addition, the new building offers a huge expansion in capacity for the storage of trial materials, especially refrigerated storage, where pallet space has increased by five times.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
